Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Renal Cell Carcinoma

New Reference: Nivolumab and Cabozantinib for Advanced RCC

Ulas D. Bayraktar, MD

Melanoma

New Indication: Adjuvant Pembrolizumab for Melanoma

Ulas D. Bayraktar, MD

Acute myeloid leukemia

New Protocol: Ivosidenib and Azacitidine in IDH1-Mutated AML

Ulas D. Bayraktar, MD

Prostate Cancer

New Protocol: Abiraterone with DOCEtaxel in CRPC

Ulas D. Bayraktar, MD

Prostate Cancer

New Indication: Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

Ulas D. Bayraktar, MD

Cervical Cancer

New Reference: Cemiplimab for Cervical Cancer

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2-Mutant NSCLC

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Indication: Nivolumab in Esophageal SCC

Ulas D. Bayraktar, MD

Hodgkin Lymphoma

New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma

Ulas D. Bayraktar, MD

Renal Cell Carcinoma

New Reference: Nivolumab and Cabozantinib for Advanced RCC

Open-label, randomised, phase 3 trial (CheckMate 9ER) Previously untreated advanced or metastatic clear-cell renal cell carcinoma Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/d

New Indication: Adjuvant Pembrolizumab for Melanoma

Double-blind, randomised, phase 3 study (KEYNOTE-716) Newly diagnosed, completely resected stage IIB or IIC melanoma Pembrolizumab (n=483) or placebo (n=486)

Acute myeloid leukemia

New Protocol: Ivosidenib and Azacitidine in IDH1-Mutated AML

Double-blind, randomized, placebo-controlled, phase 3 trial Newly diagnosed IDH1-mutated acute myeloid leukemia Ineligible for intensive induction chemotherapy Oral ivosidenib and

Prostate Cancer

New Protocol: Abiraterone with DOCEtaxel in CRPC

Open-label, randomised, phase 3 study (PEACE-1) De novo metastatic prostate adenocarcinoma Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/

Prostate Cancer

New Indication: Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

International, multicenter, phase 3 trial (ARASENS) Metastatic, hormone-sensitive prostate cancer Darolutamide (n=651) or placebo (n=654) with androgen-deprivation therapy and doce

Cervical Cancer

New Reference: Cemiplimab for Cervical Cancer

Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1) Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy Cemiplimab (n=304) or sin

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2-Mutant NSCLC

Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight

GastroEsophageal Cancer

New Indication: Nivolumab in Esophageal SCC

Global, randomized, open-label, phase 3 trial (CheckMate 648) Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy f

Hodgkin Lymphoma

New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma

Multicenter, randomized, open-label trial Stage 3 or 4 advanced Hodgkin’s lymphoma A+AVD (n:664) or ABVD (n:670)

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag